Reiterate top-line data readout from CBeyond™ Phase 2a study of nimacimab planned late Q3/early Q4 2025Patient enrollment in ...

Eli Lilly’s LLY 38% revenue growth and 61% non-GAAP EPS growth in the second quarter were above consensus expectations.

Mounjaro manufacturer Eli Lilly has unveiled the test results of its new oral GLP-1 medication, orforglipron. The obesity pill, which is designed to be taken daily by patients who are severely ...

Are weight loss shots like Ozempic and Wegovy safe long-term? It’s complicated. Some early studies suggest thyroid concerns ...

Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo ...

Eli Lilly and Company (NYSE:LLY) is one of the most profitable growth stocks to buy according to billionaires. On August 1, ...

From the price of forthcoming weight loss pill orforglipron, to Most Favored Nation drug pricing and the market battle with ...

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

Redditors are complaining their long-term Mounjaro use is causing their hair to fall out in clumps. Experts claim sorting your diet out may fix the issue.

No revenue was recorded as the company remains pre-commercial, in line with analyst expectations. R&D and G&A expenses surged 47% and 191% year over year as apitegromab advanced toward anticipated U.S ...

CINCINNATI — U.S. Customs and Border Protection (CBP) and the U.S. Food and Drug Administration (FDA) at the port of ...

Weight loss medications such as Wegovy and Zepbound have garnered an enormous amount of attention recently for their ability to help some users lose significant amounts of weight relatively easily.